(Q33589173)

28 July 2017

1 reference

title

Herpes simplex virus vaccines. (English)

1 reference

28 July 2017

Bernstein DI

1

1 reference

28 July 2017

Stanberry LR

series ordinal

2

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

17

1 reference

28 July 2017

issue

13-14

1 reference

28 July 2017

page(s)

1681-1689

1 reference

28 July 2017

cites work

Herpes simplex viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Antiviral chemotherapy in genital herpes simplex virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Herpes Simplex Virus Type 2 in the United States, 1976 to 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

The quest for a herpes simplex virus vaccine: background and recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Herpes simplex virus vaccines as immunotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Multiple smallpox vaccinations in the treatment of recurrent herpes simplex

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Vaccination for recurrent herpes simplex infection; initiation of a new disease site following the use of unmodified material containing the live virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Reactions of autoinoculation for recurrent herpes simplex

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Herpes simplex virus glycoprotein treatment of recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Herpes Simplex Virus Type-1 Glycoprotein D Gene: Nucleotide Sequence and Expression inEscherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Efficacy of a Recombinant Glycoprotein D Subunit Vaccine on the Development of Primary and Recurrent Ocular Infection with Herpes Simplex Virus Type 1 in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Immunotherapy of Recurrent Genital Herpes with Recombinant Herpes Simplex Virus Type 2 Glycoproteins D and B: Results of a Placebo‐Controlled Vaccine Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye model

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

DNA Immunization against Herpes Simplex Virus: Enhanced Efficacy Using a Sindbis Virus-Based Vector

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

DNA immunization against experimental genital herpes simplex virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900434-4

7 January 2021

10.1016/S0264-410X(98)00434-4

Identifiers

DOI

1 reference

28 July 2017

1 reference